A PARALLEL, DOUBLE-BLIND, MULTICENTER, WORLDWIDE STUDY TO EVALUATE THE TOLERABILITY OF MK-0524A AGAINST PROLONGED RELEASE NIACINE

MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2006年9月25日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. The patient is male or female ≥ 18 and ≤ 80 years old on the day they sign the informed consent.
•2. The patient understands the study procedures, alternative treatments available and the risks involved in the study and agrees to voluntarily participate by giving written informed consent.
•3. Contraception for female patients of childbearing age: A patient of childbearing age agrees to abstain or use 2 acceptable methods of birth control during the course of the study.
•4. The patient is an appropriate candidate for niacin therapy.
•5. Patient has TG <500 mg / dL (5.65 mmol / L) at Visit 1 or within 6 months prior to Visit 1.
•6. The patient s glycemic condition has been determined before Visit 2.

排除标准

•1. The patient is pregnant or breastfeeding, or waiting to conceive during the study, including the 14-day follow-up after the study.
•2. The patient has a history of malignancy <5 years before signing the informed consent.
•3. The patient is waiting to donate eggs during the study, including the 14-day follow-up.
•4. The patient has a history or current evidence of any condition, therapy or abnormality of the laboratory tests that could confuse the results of the study, interfere with the participation of the patient during the entire course of the study, or not be the most convenient for the patient to participate.
•5. The patient consumes more than 2 alcoholic drinks per day.
•6. It is unlikely that the patient sticks to the study procedures, respects appointments or is planning to move during the study.
•7. The patient is participating, currently or has participated in a study with: a) A compound under investigation within 30 days prior to Visit 1. b) A lipid modifying compound within 8 weeks prior to the Visit one.
•8. The patient has donated and / or received blood.
•9. The patient has the following excluding values: a) Creatinine> 2.0 mg / dL. b) ALT (SGPT)> 1.5 x ULN. c) AST (SG0T)> 1.5 x ULN. d) CK> 2 x ULN.
•10. The patient is a user of recreational or illicit drugs or has had a recent history of alcohol or drug abuse.
•11. The patient is currently experiencing hot flushes due to menopause.
•12. The patient is currently involved, or plans to become involved during the study, in vigorous exercise or an aggressive diet regimen.
•13. The patient has evidence of ischemic cardiovascular disease.
•14. The patient has 2 or more risk factors for coronary heart disease.
•15. The patient suffers from uncontrolled / unstable cardiac arrhythmias.
•16. The patient suffers from chronic heart failure.
•17. The patient suffers from Type 1 or Type 2 diabetes mellitus and meets one or more of the following criteria: a) Has poor control. b) The disease has been diagnosed recently. c) The patient has recently experienced repeated hypoglycaemia or unstable glycemic control. d) The patient is receiving new or recently adjusted antidiabetic pharmacotherapy within 3 months prior to the randomization visit. e) The patient has LDL-C ≥ 130 mg / dL (3.37 mmol / L).
•18. The patient suffers from an uncontrolled endocrine or metabolic disease known to influence lipids or serum lipoproteins.
•19. The patient suffers from nephrotic syndrome or other clinically significant kidney disease.
•20. The patient has suffered from active peptic ulcer within 3 months prior to Visit 1.
•21. The patient has had a gout episode within the 1 year period prior to Visit 1.
•22. The patient has a history of hypersensitivity to niacin or products containing niacin.
•23. The patient suffers from uncontrolled hypertension in Visit 1.
•24. The patient has a history of ileal bypass, gastric bypass or other significant condition associated with malabsorption.
•25. The patient has active or chronic hepatobiliary or hepatic disease.
•26. The patient is HIV positive.
•27. The patient has initiated therapy with lipid modifying agents within 6 weeks before Visit 1.
•28. The patient has begun treatment with orlistat, sibutramine or another anti-obesity medication within 3 months prior to randomization.
•29. The patient is currently taking niacin ≥ 50 mg / day.
•30. The patient is curre

研究者

发起方

MERCK SHARP & DOHME PERU S.R.L.,

相似试验

未知

不适用

A MULTI-CENTRE, DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TAFENOQUINE (SB-252263, WR238605) IN SUBJECTS WITH PLASMODIUM VIVAX MALARIA.

PER-031-11GlaxoSmithKline,155

进行中（未招募）

不适用

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF ADAPALENE/BENZOYL PEROXIDE TOPICAL GEL COMPARED WITH ADAPALENE TOPICAL GEL, 0.1%; BENZOYL PEROXIDE TOPICAL GEL, 2.5% AND TOPICAL GEL VEHICLE IN SUBJECTS WITH ACNE VULGARIS

EUCTR2006-004215-21-DEGalderma Research & Development Inc.1,656

进行中（未招募）

不适用

EUCTR2006-004215-21-HUGalderma Research & Development Inc.1,656

进行中（未招募）

不适用

A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER EFFICACY AND TOLERANCE OF F2695 SR IN MAJOR DEPRESSIVE DISORDERMajor Depressive Disorder

EUCTR2006-002404-34-CZPierre Fabre Médicament534

进行中（未招募）

不适用

EUCTR2006-002404-34-EEPierre Fabre Médicament534